A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)

At present, the treatment methods for recurrent cancers are very limited. The immune checkpoint inhibitors (ICBs) is a promising new directions for recurrent lung cancer/ esophageal cancer / cervical cancer, but the clinical response rate is insufficient. Pulse low-dose rate radiotherapy (PLDR) is a new technology in recent years, which uses continuous pulse low-dose rate irradiation to induce hypersensitivity in tumors, and its clinical safety has been verified. Compared to conventional radiotherapy, PLDR has advantages in protecting the lymphatic system and relieving the immune barrier, but

Trial Details

NCT ID
NCT06232083
Phase
PHASE1
Sponsor
Anhui Provincial Hospital
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • PLDR+Cardunizumab
Locations (sample)
  • Hefei, British Columbia, China|31.86389,117.28083

Key Eligibility Criteria

  • Patients must meet all the following criteria to be enrolled:
  • The subjects voluntarily joined the study, signed informed consent, had good compliance and were willing to cooperate with the follow-up;
  • There is no limit for men and women, ranging in age from 18 to 75 years old (including 18 and 75 years old);
  • Pathologically confirmed esophageal cancer, lung cancer or cervical cancer;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →